Note 18 - Subsequent Events

12 Months Ended

Dec. 31, 2019

Notes to Financial Statements

Subsequent Events [Text Block]

( 18 ) Subsequent Events

On

November 26, 2019,

at BioCardia’s

2019

Annual Meeting of Stockholders, the Company’s stockholders approved a

one

-time repricing of certain outstanding stock options granted to service providers (covering a total of

515,036

shares of BioCardia’s common stock with per share exercise prices between

$10.05

and

$97.21

) under the

2002

Stock Plan and the

2016

Equity Incentive Plan. Pursuant to such approval, as of

January 29, 2020

the exercise price of such options was automatically repriced to

$5.32

per share (the “Repricing”). This is being accounted for as a modification and the incremental compensation cost to be recorded in the Consolidated Statement of Operations is

not

expected to be material.

In

March 2020,

the World Health Organization declared the outbreak of COVID-

19,

a novel strain of Coronavirus, a global pandemic. This outbreak is causing major disruptions to businesses and financial markets worldwide as the virus spreads. The extent of the effect on the Company’s operational and financial performance will depend on future developments, including the duration, spread and intensity of the pandemic, and governmental, regulatory and private sector responses, all of which are uncertain and difficult to predict. Although the Company is unable to estimate the financial effect of the pandemic at this time, if the pandemic continues to evolve into a severe worldwide health crisis, it could have a material adverse effect on the Company’s business, clinical development programs, clinical trials, and ability to raise future equity or debt financing. The financial statements do

not

reflect any adjustments as a result of the pandemic.